n-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine profile

Description

N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine: structure given in first source; RN given refers to (+-)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	124844
CHEMBL ID	268689
SCHEMBL ID	1740907
MeSH ID	M0146714

Synonyms (24)

Synonym
eden
mbdb
n-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine
1,3-benzodioxole-5-ethanamine, alpha-ethyl-n-methyl-, (+-)-
CHEMBL268689
1-(1,3-benzodioxol-5-yl)-n-methylbutan-2-amine
103818-46-8
n-methyl-1-(3,4-methylenedioxyphenyl)-2-butanamine
1,3-benzodioxolyl-n-methylbutanamine
SCHEMBL1740907
USWVWJSAJAEEHQ-UHFFFAOYSA-N
1,3-benzodioxole-5-ethanamine, .alpha.-ethyl-n-methyl-
3,4-methylenedioxy-n-methyl-alpha-ethylphenylethylamine
J360.170F ,
135795-90-3
n-methyl-1,3-benzodioxolylbutanamine
unii-e8hmq4f9jq
methyl-j
1,3-benzodioxole-5-ethanamine, alpha-ethyl-n-methyl-
n-methyl-1-(1,3-benzodioxol-5-yl)-2-butylamine
e8hmq4f9jq ,
DTXSID70894039
Q416405
[1-(2h-1,3-benzodioxol-5-yl)butan-2-yl](methyl)amine

Bioassays (8)

Assay ID	Title	Year	Journal	Article
AID176839	Tested for drug-discrimination stimulus effect in S-1c trained rats	1993	Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23	Synthesis and pharmacological examination of benzofuran, indan, and tetralin analogues of 3,4-(methylenedioxy)amphetamine.
AID191212	Compound was tested for hallucinogenic activity in rats at 1.46 dose(mg/kg); Number of rats selecting the LSD lever/ number of rats responding (0/8)	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class.
AID178389	Effective dose for drug discrimination assay in rats using (+)-MBDB as training drug.	1998	Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6	Synthesis and pharmacological evaluation of ring-methylated derivatives of 3,4-(methylenedioxy)amphetamine (MDA).
AID91217	Compound tested for hallucinogenic activity in humans was reported; Value reported in (A)= Mescaline units	1998	Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20	The frontier orbital phase angles: novel QSAR descriptors for benzene derivatives, applied to phenylalkylamine hallucinogens.
AID191228	Compound was tested for hallucinogenic activity in rats at 2.07 dose(mg/kg); 0/0, highest dose tested	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class.
AID191224	Compound was tested for hallucinogenic activity in rats at 1.95 dose(mg/kg); Number of rats selecting the LSD lever/ number of rats responding (1/7)	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class.
AID191398	Compound was tested for hallucinogenic activity in rats at the dose 0.37(mg/kg); Number of rats selecting the LSD lever/ number of rats responding (0/8)	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class.
AID191401	Compound was tested for hallucinogenic activity in rats at the dose 0.73(mg/kg); Number of rats selecting the LSD lever/ number of rats responding (0/8)	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (31)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	4 (12.90)	18.7374
1990's	12 (38.71)	18.2507
2000's	13 (41.94)	29.6817
2010's	2 (6.45)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (2.70%)	5.53%
Reviews	1 (2.70%)	6.00%
Case Studies	2 (5.41%)	4.05%
Observational	0 (0.00%)	0.25%
Other	33 (89.19%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Description	Relationhip Strength	Studies	Classes	Roles
3,4-methylenedioxyamphetamine	[no description available]	medium	37	benzodioxoles
n-methyl-3,4-methylenedioxyamphetamine	[no description available]	medium	17	amphetamines; benzodioxoles	neurotoxin
lysergic acid diethylamide	[no description available]	medium	2	ergoline alkaloid; monocarboxylic acid amide; organic heterotetracyclic compound	dopamine agonist; hallucinogen; serotonergic agonist
1-(3,4-methylenedioxyphenyl)-2-butanamine	[no description available]	medium	5	benzodioxoles
5-methoxy-6-methyl-2-aminoindan	[no description available]	medium	5
4-iodo-2,5-dimethoxyphenylisopropylamine	[no description available]	medium	3	amphetamines; dimethoxybenzene; organoiodine compound
dextroamphetamine	[no description available]	medium	2	1-phenylpropan-2-amine	adrenergic agent; adrenergic uptake inhibitor; dopamine uptake inhibitor; dopaminergic agent; neurotoxin; sympathomimetic agent
4-iodoamphetamine	[no description available]	medium	1
4-methylthioamphetamine	[no description available]	medium	3
mescaline	[no description available]	medium	1	methoxybenzenes; phenethylamine alkaloid; primary amino compound	hallucinogen
mmda	[no description available]	medium	1
2,5-dimethoxy-4-ethylamphetamine	[no description available]	medium	1	amphetamines
2,4,5-trimethoxyphenylisopropylamine	[no description available]	medium	1
4-methoxyamphetamine	[no description available]	medium	2
2,5-dimethoxy-4-bromoamphetamine	[no description available]	medium	2
2,5-dimethoxyamphetamine	[no description available]	medium	1
2,5-dimethoxy-4-methylamphetamine	[no description available]	medium	1
2-(4-bromo-2,5-dimethoxyphenyl)ethylamine	[no description available]	medium	1	2-arylethylamine
n-hydroxy-1-(3,4-methylenedioxyphenyl)-2-aminopropane	[no description available]	medium	1
3,4-methylenedioxyethamphetamine	[no description available]	medium	10	benzodioxoles; secondary amino compound
1-(2,5-dimethoxy-4-nitrophenyl)-2-aminopropane	[no description available]	medium	1
4-chloro-2,5-dimethoxyamphetamine	[no description available]	medium	1
2-(2,5-dimethoxy-4-methylphenyl)cyclopropylamine	[no description available]	medium	1
4-iodo-2,5-dimethoxy-beta-phenethylamine	[no description available]	medium	1
2,5-dimethoxy-4-ethylthiophenethylamine	[no description available]	medium	1
2,5-dimethoxy-4-n-propylthiophenethylamine	[no description available]	medium	1
4-methoxymethamphetamine	[no description available]	medium	2
methamphetamine	[no description available]	medium	4	amphetamines; secondary amine	central nervous system stimulant; environmental contaminant; neurotoxin; psychotropic drug; xenobiotic
phenethylamine	[no description available]	medium	1	alkaloid; aralkylamine; phenylethylamine	Escherichia coli metabolite; human metabolite; mouse metabolite
benzofuran	[no description available]	medium	1	1-benzofurans; benzofuran
benzofurans	[no description available]	medium	1
6-(2-aminopropyl)benzofuran	[no description available]	medium	1
5-APB	[no description available]	medium	1	benzofurans
methylone	[no description available]	medium	2	benzodioxoles
2-ethylammonio-1-(3,4-methylenedioxyphenyl)propane-1-one chloride	[no description available]	medium	1
2-methylamino-1-(3,4-methylenedioxyphenyl)butan-1-one	[no description available]	medium	1	butanone
haloperidol	[no description available]	medium	1	aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol	antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist
apomorphine	[no description available]	medium	1	aporphine alkaloid	alpha-adrenergic drug; antidyskinesia agent; antiparkinson drug; dopamine agonist; emetic; serotonergic drug
fenclonine	[no description available]	medium	1	phenylalanine derivative
citalopram	[no description available]	medium	2	2-benzofurans; cyclic ether; nitrile; organofluorine compound; tertiary amino compound
oxidopamine	[no description available]	medium	1	benzenetriol; catecholamine; primary amino compound	drug metabolite; human metabolite; neurotoxin
monomethylpropion	[no description available]	medium	1	aromatic ketone; secondary amino compound
amphetamine	[no description available]	medium	5	primary amine
4-fluoroamphetamine	[no description available]	medium	1
3,4-dihydroxyphenylacetic acid	[no description available]	medium	1	catechols; dihydroxyphenylacetic acid	human metabolite
fluoxetine	[no description available]	medium	4	(trifluoromethyl)benzenes; aromatic ether; secondary amino compound
oxytocin	[no description available]	medium	1	heterodetic cyclic peptide; peptide hormone	oxytocic; vasodilator agent
pituitrin	[no description available]	medium	1
gr 127935	[no description available]	medium	1	1,2,4-oxadiazole; benzamides; N-alkylpiperazine; N-arylpiperazine
oxadiazoles	[no description available]	medium	1
3,4-dimethoxyamphetamine	[no description available]	medium	1
p-chloroamphetamine	[no description available]	medium	1
5,6-methylenedioxy-2-aminoindane	[no description available]	medium	1	benzodioxoles
hydroxyindoleacetic acid	[no description available]	medium	1	indole-3-acetic acids	drug metabolite; human metabolite; mouse metabolite
piperidines	[no description available]	medium	1
paroxetine	[no description available]	medium	1	aromatic ether; benzodioxoles; organofluorine compound; piperidines	antidepressant; anxiolytic drug; hepatotoxic agent; P450 inhibitor; serotonin uptake inhibitor

Condition	Relationship Strength	Studies
Amphetamine Abuse	low	1
Amphetamine Addiction	low	1
Amphetamine Dependence	low	1
Amphetamine-Related Disorders	low	1
Anochlesia	low	1
Atherosclerotic Parkinsonism	low	1
Catalepsy	low	1
Cerea Flexibilitas	low	1
Chemical Dependence	low	2
Drug Abuse	low	2
Drug Addiction	low	2
Drug Dependence	low	2
Drug Habituation	low	2
Drug Use Disorders	low	2
Flexibility, Waxy	low	1
Idiopathic Parkinson Disease	low	1
Idiopathic Parkinson's Disease	low	1
Lewy Body Parkinson Disease	low	1
Lewy Body Parkinson's Disease	low	1
Nervous System Diseases	low	1
Nervous System Disorders	low	1
Neurologic Disorders	low	1
Neurological Disorders	low	1
Organic Mental Disorders, Substance-Induced	low	2
Paralysis Agitans	low	1
Parkinson Disease	low	1
Parkinson Disease, Idiopathic	low	1
Parkinson Disease, Secondary	low	1
Parkinson Disease, Secondary Vascular	low	1
Parkinson Disease, Symptomatic	low	1
Parkinson's Disease	low	1
Parkinson's Disease, Idiopathic	low	1
Parkinson's Disease, Lewy Body	low	1
Parkinsonism, Secondary	low	1
Parkinsonism, Symptomatic	low	1
Prescription Drug Abuse	low	2
Primary Parkinsonism	low	1
Secondary Parkinsonism	low	1
Secondary Vascular Parkinson Disease	low	1
Sensitivity and Specificity	low	1
Substance Abuse	low	2
Substance Addiction	low	2
Substance Dependence	low	2
Substance Use	low	2
Substance Use Disorders	low	2
Substance-Related Disorders	low	2
Symptomatic Parkinson Disease	low	1

Research Highlights

Safety/Toxicity (2)

Article	Year
Cytotoxic effects of 3,4-methylenedioxy-N-alkylamphetamines, MDMA and its analogues, on isolated rat hepatocytes. Archives of toxicology, Volume: 83, Issue: 1	2009
Neurotoxic effects of the alpha-ethyl homologue of MDMA following subacute administration. Pharmacology, biochemistry, and behavior, Volume: 33, Issue: 1	1989
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Dosage (3)

Article	Year
Ecstasy (MDMA, MDA, MDEA, MBDB) consumption, seizures, related offences, prices, dosage levels and deaths in the UK (1994-2003). Journal of psychopharmacology (Oxford, England), Volume: 20, Issue: 3	2006
Behavioral effects of the highly selective serotonin releasing agent 5-methoxy-6-methyl-2-aminoindan. European journal of pharmacology, Jun-02, Volume: 258, Issue: 1-2	1994
Neurotoxic effects of the alpha-ethyl homologue of MDMA following subacute administration. Pharmacology, biochemistry, and behavior, Volume: 33, Issue: 1	1989
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

n-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine